Bristol Myers Squibb pauses CAR-T therapy trials
According to STAT News, which cites The Wall Street Journal, Bristol Myers Squibb informed regulators, researchers and patient advocacy groups in early June that it was pausing trials of CAR-T therapy for the treatment of autoimmune diseases. The company halted the study after identifying life-threatening side effects.
When the pause became known
The suspension of the trials became known only this week, following the publication of an analytical note and media reports. According to STAT News, this raised questions about the transparency of reporting clinical trial data.
More current news is available on the UA.News Telegram channel Telegram.
Mention of Novartis research
The article also mentions three deaths in similar studies conducted by Novartis. STAT News notes these cases alongside the report of Bristol Myers Squibb's pause.
